Earnings before interest, taxes, depreciation and amortization (EBITDA) rose 45% to Rs 869 crore, while EBITDA margin expanded to 22.3% from the year-ago period.
“We delivered strong double-digit revenue growth in the third quarter, reflecting disciplined execution across markets and keeping us on track to deliver on our near-term expectations,” said Glenn Saldanha, chairman and chief executive officer.
He added that the company’s innovative portfolio, including Ryaltris and Winlevi, together with its partners’ oncology assets, is expected to contribute meaningfully to growth, positioning the company for a structurally stronger and more sustainable trajectory.
Formulations in India remained the biggest growth driver, with sales up 22% to Rs 1,298 crore. North America revenues rose 24.2% year-on-year to Rs. 970 crore, helped by licensing revenues related to ISB 2001. After deducting licensing revenues for ISB 2001, year-on-year core business growth for the North America region was 4.1% in Q3 FY26.
During the quarter, Glenmark also received positive results from the U.S. Food and Drug Administration for its plant in Monroe, North Carolina, allowing it to restart commercial production. Sales in Europe grew 9.1% year-on-year to Rs. 796 crore supported by seasonal demand for respiratory products, new launches and stable performance in key markets such as Germany and Netherlands. Emerging markets reported revenues of Rs 811 crore, up 8.4% on strong growth in Russia and Latin America, while parts of the Middle East and Africa remained subdued. End
#Glenmarks #thirdquarter #profit #rises #strong #performance #India